LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of O
Eli Lilly (LLY) received FDA approval for Onswik, a once-weekly insulin for type 2 diabetes. The company's stock is deemed 26.0% undervalued with a GF Value of $1,554.72 vs. current price $1,150.99. LLY has a GF Score of 96/100, reflecting strong financial health and growth. Insider selling activity is noted, but institutional investors show confidence.
How this was made
The 30-second read
Why it matters
The approval expands Lilly's cardiometabolic pipeline, offering a differentiated insulin product that could capture market share from daily insulin competitors.
Market read
A material regulatory event for a large‑cap pharma, likely to influence stock price and sector sentiment.
What to watch
Potential manufacturing scale‑up challenges and pricing pressure in emerging markets.
Background
Eli Lilly announced FDA approval of Onswik, a once‑weekly basal insulin, following successful Phase 3 trials and prior approvals abroad.
Ticker impact
FDA approved Eli Lilly's once‑weekly basal insulin Onswik, a new product launch for type 2 diabetes.
Potential upside of 5‑10% over the next 3‑6 months as sales ramp.
Regulatory clearance is a material catalyst; the drug addresses a large market and has no direct competition in the weekly‑insulin space.
Market effects
Strengthens the healthcare/biopharma sector, especially peers in diabetes therapeutics.
Positive for U.S. pharma stocks; may lift related ADRs.
Adds to global insulin market dynamics, could pressure competitors.
Counterpoint
Insider selling and high valuation multiples may limit upside; reimbursement risk could temper growth.
Key entities
- CompanyEli Lilly and Co
US‑listed pharmaceutical company (ticker LLY) receiving FDA approval.
- ProductOnswik
Once‑weekly basal insulin for adults with type 2 diabetes.
